Excited to disclose that Philochem and Blue Earth Diagnostics (a Bracco Company) are collaborating on OncoFAP for diagnostic imaging and medical applications. The first three patients FAPrimo clinical trial have been successfully imaged with 68Ga-OncoFAP and we look forward to progressing this program with a world leader in the diagnostic imaging field.
Info
Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group. Philochem is based in Otelfingen (Zurich, Switzerland) and was founded in 2006, with the mission to innovate ligand discovery and medicinal target identification. Philochem has discovered innovative methodologies for biotechnology product development: - isolation of human monoclonal antibodies from large combinatorial libraries; - development of armed antibodies (immunocytokines and antibody-drug conjugates); - discovery and validation of vascular markers of pathology using a perfusion-based chemical proteomics approach; - design, construction and screening of DNA-encoded chemical libraries of unprecedented quality and size. These technologies are integrated into drug discovery programs. The most promising candidate products are further developed in the Siena-based Philogen facilities. Here production according to GMP standards and clinical trials are conducted with the aim of developing superior products for the imaging and treatment of serious angiogenesis-related diseases. Philochem has a proven track record in partnering activities, and is currently involved in several projects with leading pharmaceutical companies interested in Philochem’s innovative technology platforms.
- Website
-
http://www.philochem.ch
Externer Link zu Philochem AG
- Branche
- Forschungsdienstleistungen
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Otelfingen
- Art
- Privatunternehmen
- Gegründet
- 2006
Orte
-
Primär
Libernstrasse 3
Otelfingen, 8112, CH
Beschäftigte von Philochem AG
Updates
-
Stiamo #assumendo per un ruolo di “Industrial PHD Student” a Otelfingen, Zurich. Candidati subito o condividi questo post con la tua rete.
-
Stiamo #assumendo per un ruolo di “Industrial PhD Student - Chemistry” a Otelfingen, Zurich. Candidati subito o condividi questo post con la tua rete.
-
Delighted to invite you to our virtual briefing on 2 October 2023 to discuss the Company’s Half Year 2023 Results. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, and Dr. Emanuele Puca, Head of Investor Relations, will host a 1-hour live webcast and conference call for analysts on 2 October 2023 at 10:00 ET / 15:00 BST / 16:00 CET. The presentation will be followed by a Q&A session. Following the link below to register to the event: https://lnkd.in/esZmA6sZ
-
Thrilled to share another article published by CHEMIEXTRA on Philogen science. Follow the link to learn more about Machine Learning models applied to our DNA Encoded Chemical Library Technology. https://lnkd.in/ePjF9wtH
-
We are excited to share the recent interview of CH media to our CEO and CSO Prof. Dario Neri! #Philogen #cancertherapy #CHmedia